Chemically modified, non-anticoagulant heparin derivatives are potent galectin-3 binding inhibitors and inhibit circulating galectin-3-promoted metastasis
Year: 2015
Type: article
Abstract: // Carrie A. Duckworth 1, * , Scott E. Guimond 2, * , Paulina Sindrewicz 1 , Ashley J. Hughes 2, 4 , Neil S. French 3 , Lu-Yun Lian 2 , Edwin A. Yates 2 , D. Mark Pritchard 1 , Jonathan M. Rhodes 1 , Jeremy E. Turnbull 2 , Lu-Gang Yu 1 1 Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom 2 Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom 3 Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom 4 Diamond Light Source Ltd, Harwell Innovation Campus, Didcot, United Kingdom * These authors have contributed equally to this work Correspondence to: Lu-Gang Yu, e-mail: [email protected] Jeremy E. Turnbull, e-mail: [email protected] Keywords: galectin-3, metastasis, heparin Received: September 29, 2014 Accepted: June 12, 2015 Published: June 23, 2015 ABSTRACT Concentrations of circulating galectin-3, a metastasis promoter, are greatly increased in cancer patients. Here we show that 2- or 6-de- O -sulfated, N -acetylated heparin derivatives are galectin-3 binding inhibitors. These chemically modified heparin derivatives inhibited galectin-3-ligand binding and abolished galectin-3-mediated cancer cell-endothelial adhesion and angiogenesis. Unlike standard heparin, these modified heparin derivatives and their ultra-low molecular weight sub-fractions had neither anticoagulant activity nor effects on E-, L- or P-selectin binding to their ligands nor detectable cytotoxicity. Intravenous injection of such heparin derivatives (with cancer cells pre-treated with galectin-3 followed by 3 subcutaneous injections of the derivatives) abolished the circulating galectin-3-mediated increase in lung metastasis of human melanoma and colon cancer cells in nude mice. Structural analysis using nuclear magnetic resonance and synchrotron radiation circular dichroism spectroscopies showed that the modified heparin derivatives bind to the galectin-3 carbohydrate-recognition domain. Thus, these chemically modified, non-anticoagulant, low-sulfated heparin derivatives are potent galectin-3 binding inhibitors with substantial potential as anti-metastasis/cancer drugs.
Source: Oncotarget
Institutions: University of Liverpool, Diamond Light Source
Language: English
Topic: Galectins and Cancer Biology
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: diamond
Estimated APC paid: $2,736
OpenAlex ID: W2130812849
